Blend Therapeutics Inc.

134 Coolidge Avenue

Watertown, Massachusetts  02472

Tel: 617. 923.4100

Drew Fromkin
President and CEO



Blend Therapeutics Inc.

Flagship Partners:  David Berry, Ed Kania
Initial Investment: 

Blend Therapeutics is a biopharmaceutical company with an innovative platform for creating novel cancer therapies designed to overcome the biological barriers that limit the effectiveness of many cancer medicines today. At the center of the company’s drug development is its proprietary Pentarin platform, which creates novel, miniaturized biologic drug conjugates (mBDCs) encapsulated into patented nanoparticles. Blend’s pipeline includes its lead drug candidate, BTP-114, a novel, personalized cisplatin prodrug derived from the company’s R&D heritage in platinum drugs, which is expected to enter the clinic in mid-2015.

Ed Kania is on the Board of Directors.